Novavax (NASDAQ:NVAX) has amended its agreement with Serum Institute of India Private Limited (SIIPL), under which the latter will manufacture the antigen component of COVID-19 vaccine candidate NVX-CoV2373. The deal increases manufacturing capacity to more than 2B doses annually when all planned changes are implemented by mid-2021.
NVAX says the antigen component is being made at its site in Bohumil, Czech Republic, plus six other locations, including SIIPL.
The Matrix-M adjuvant is being made at three locations, including its site in Uppsala, Sweden.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.